Tag: CHMJF

Blue Horseshoe Stocks: CHMJF Review

chemistree-technology-logo-1
Chemistree Technology, Inc.
(OTCMKTS:CHMJF) (CSE:CHM)

We are circling back to revisit CHMJF this morning, a stock that we recently profiled operating in the cannabis space. Our regular followers are certainly aware of our predisposition toward the industry, as a thriving, relatively new market space that is setting up to flourish well into the future.

The company is actively pursuing the development of vertically integrated cannabis assets in multiple states, including the design and build-out of tens of thousands of square feet of greenhouse and processing facility space. The company has interests in both the retail and medical sectors, and in both flower and by-product form (e.g. CBD/Hemp Extract).

We previously commented on the incredible past year the company’s had in terms of executing its strategy of acquiring and developing assets in various areas of the cannabis business. That’s one of the primary draws for us in this case. at the end of last month, CHMJF management laid out what we can expect from the company in the next year.

First off, CHMJF plans to continue to seek out new opportunities in the Western United States, in addition to its Sugarleaf cannabis brand in Washington and prospective grow/processing operation in marijuana ‘hot zone’, Desert Hot Springs, California. It will also optimize the Sugarleaf operation through expansion of its existing facilities, slated for completion in August of this year. In terms of the California project, we’re looking at a slightly longer timetable, with the first greenhouse tentatively scheduled to go up in the 1st quarter of 2020.

We’re very interested to continue tracking the multiple irons the company has in the fire, but for the time being, we are also very interested in the technical setup of the chart.

The early spring brought solid moves for CHMJF stock, as it traded up from a low of .3145 in March, to as much as .597 in April. After a period of consolidation, the stock recently saw a low of .313, and has begun to show signs of another leg-up. After seeing that 90% move previously, we are very interested to see if CHMJF can mount another run of a similar or perhaps even more significant nature.

We encourage readers to launch their own due diligence into CHMJF, and also check out the following video presentation of the current CHMJF chart. 

CHMJF VIDEO CHART:

_____

FRESH CHMJF NEWS: 

VANCOUVER, June 10, 2019 /PRNewswire/ – Chemistree Technology Inc. (CSE: CHM) (US OTCQB: CHMJF) (the “Company” or “Chemistree”), is pleased to announce that its partner Applied Cannabis Sciences of New Jersey (“ACS”), is readying an Application under the new Request for Applications (RFA) program announced by the Department of Health on June 3, 2019. In total, the Department will seek up to 24 cultivation endorsements, up to 30 manufacturing endorsements, and up to 54 dispensary endorsements. As allowable, ACS will be applying for all three permit types, creating a vertically integrated model for the business. (>>Read Full PR)
_____

For More Information on CHMJF, visit:
chemistree.ca/

Blue Horseshoe Stocks: CHMJF Special Report

chemistree-technology-logo-1
Chemistree Technology, Inc. – Special Report
(OTCMKTS:CHMJF) (CSE:CHM)
.
Our primary order of business today is to profile a stock that we’ve never mentioned on our websites before, however, one that is actively involved in a market space that we’ve covered extensively. Cannabis has been at or near the top of our interests ever since our coverage of the legendary Green Rush of 2012, and continuing through to present-day.

Chemistree Technology Inc. is self-billed as an investment company which provides turn-key solutions for the regulated cannabis industry through the development of vertically integrated cannabis assets, including licensed cultivation, processing, distribution and retail facilities.

Perhaps the most impressive aspect of CHMJF is the rapidity with which the company has gone about executing its corporate strategy. In just the past year, it has acquired and/or developed cannabis assets in California and Washington State, with even more currently under construction.

In Washington State last May, the company acquired the Sugarleaf cannabis brand, along with the growing and processing facility that produces it, and all associated licenses. Sugarleaf branded cannabis is currently available in more than twenty retail locations, with plans to expand that to more than a hundred outlets in the next year. The company expects to generate roughly $2.7M in 2019 revenue for this facility alone.

In California, Chemistree has arranged a strategic collaboration with a Humboldt county cannabis-to-CBD processing company. CHMJF provided a $450K loan in exchange for immediate access to the California markets and the ability to purchase cannabis for processing at the facility, which it expects to bring in as much as $1.5M in revenue in 2019 alone.

Additionally, the company purchased 9.55 acres of land in cannabis-hotspot, Desert Hot Springs, California last year. It has completed the continuous-use permit, and is currently finalizing plans for two 64,000 square foot greenhouses and a 40,000 square foot manufacturing and distribution facility, subject to the approval of the city planner’s office.

These highlights only scratch the surface of what CHMJF has accomplished in just the last year, and hint at a promising finish to 2019, along with a bright future beyond. CHMJF has quickly become an area of special interest for us in the cannabis space.
_____

IMPORTANT! All readers should take the time to
>>VIEW this IN-DEPTH OVERVIEW of CHMJF<<
_____

MOST RECENT DEVELOPMENT: VANCOUVER, April 29, 2019 /PRNewswire/ – Chemistree Technology Inc. (CSE: CHM and CHM.wt) (US OTCQB: CHMJF) (the “Company” or “Chemistree”), is pleased to announce that the Company has entered into a funding agreement with The Physician’s Choice CBD LLC of Phoenix, Arizona.

The Physician’s Choice CBD (“PCCBD”) is dedicated to research, development, and utilization of the highest quality of hemp-derived cannabidiol (CBD) combined with well-studied and effective supplements specific to help regulate and support various symptoms. The integration of extensive physician clinical experience combined with exhaustive expertise in the cannabis industry has led to the creation of The Physician’s Choice CBD. (>>View Full PR)

_____

CHMJF CHART:

_____

For More Information on CHMJF, visit:
chemistree.ca/
____

Don’t forget to check out THIS REPORT on CHMJF!